Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (NASDAQ: RLAY) is a clinical-stage precision medicine company dedicated to transforming the drug discovery process. Headquartered in Cambridge, Massachusetts, the company focuses on combining advanced computational and experimental technologies to develop life-changing therapies. Since its inception in 2016, Relay Therapeutics has been pioneering a new paradigm in the pharmaceutical industry by placing protein motion at the core of drug discovery.
The company's flagship platform, Dynamo™, integrates cutting-edge computational and experimental approaches to target protein structures that are either intractable or inadequately addressed by current therapies. This platform has enabled the development of multiple promising drug candidates, particularly in the fields of precision oncology and genetic diseases. Key product candidates include RLY-4008, RLY-2608, and GDC-1971 (formerly RLY-1971).
Relay Therapeutics' recent corporate highlights include significant advancements in its RLY-2608 program, aimed at treating patients with PI3Kα-mutated HR+/HER2- breast cancer. The company's development pipeline has been robust, with expectations to disclose innovative programs later this year.
Financially, as of March 31, 2024, Relay Therapeutics reported cash, cash equivalents, and investments totaling approximately $749.6 million. This financial stability is projected to fund the company's operations into the second half of 2026. The company’s revenue for Q1 2024 was $10 million, primarily derived from milestone payments under a collaboration agreement with Genentech, Inc.
Relay Therapeutics has also established strategic partnerships with notable entities such as Pfizer, Nextech, and Genentech, enhancing its capability to advance its clinical and preclinical programs. The company’s innovative approach has attracted significant investment from third-party ventures, including GV (formerly Google Ventures) and Alexandria Venture Investments.
Relay Therapeutics continues to push the boundaries of what’s possible in drug discovery, aiming to improve the lives of millions of patients through precision medicine.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is set to participate in two fireside chats, enhancing its visibility in the oncology and healthcare sectors. The events are scheduled for:
- Stifel 2023 Targeted Oncology Days on April 26, 2023, at 12:30 p.m. ET
- BofA Securities 2023 Health Care Conference on May 9, 2023, at 10:00 a.m. PT
Both discussions will be webcast live, accessible on Relay Therapeutics’ website, with archived replays available for 30 days post-event. Relay Therapeutics is a clinical-stage precision medicine company dedicated to revolutionizing drug discovery through innovative computational and experimental technologies, focusing on small molecule therapeutic discovery in oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) announced promising initial clinical data for RLY-2608, an investigational allosteric PI3Kα inhibitor. The data demonstrated sustained target exposure of over 80% in mutant PI3Kα inhibition across various doses. Notably, no Grade 3 hyperglycemia, rash, or diarrhea, common treatment discontinuation events, were observed. A confirmed partial response was recorded in a breast cancer patient with extensive prior therapies. The ongoing ReDiscover trial, which began in December 2021, aims to evaluate this drug's safety and efficacy in patients with unresectable or metastatic solid tumors. Relay plans to initiate expansion cohorts in the second half of 2023. The results suggest RLY-2608 could transform treatment for patients with diverse PI3Kα mutations and improve the therapeutic index of PI3Kα inhibitors.
Relay Therapeutics (Nasdaq: RLAY) announced that initial clinical data from the ReDiscover trial for RLY-2608 will be presented at the AACR Annual Meeting 2023, scheduled for April 14-19, 2023. RLY-2608 targets mutant-selective inhibitors of PI3Kα, a kinase frequently mutated in cancers, impacting approximately 13% of patients with solid tumors. The company aims to discuss the data during a conference call after the presentation. The AACR will release clinical trial abstracts on March 14, 2023, and publish them on April 14, 2023.
Relay Therapeutics (Nasdaq: RLAY) will participate in two fireside chats this March. The first event is at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 10:30 a.m. ET, and the second is the Barclays Global Healthcare Conference on March 15, 2023, at 4:05 p.m. ET. Both events will be available for live webcasting on Relay Therapeutics’ website under the Events section. Archived replays will be accessible for up to 30 days after each chat. Relay Therapeutics is a clinical-stage precision medicine company focused on innovative drug discovery using its Dynamo™ platform.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
What is Relay Therapeutics' primary focus?
Where is Relay Therapeutics headquartered?
What is the Dynamo™ platform?
What are some of Relay Therapeutics' key product candidates?
How financially stable is Relay Therapeutics?
Which significant partnerships has Relay Therapeutics established?
What recent progress has Relay Therapeutics made?
How does Relay Therapeutics plan to use its financial resources?
When was Relay Therapeutics founded?
What makes Relay Therapeutics' approach unique?
